Targeting renal cell carcinoma with NVP-BEZ235, a dual PI3K/mTOR inhibitor, in combination with sorafenib

BACKGROUND: Targeted therapies for metastatic renal cell carcinoma (RCC), including mammalian target of rapamycin (mTOR) inhibitors and small-molecule multikinase inhibitors, have produced clinical effects. However, most patients acquire resistance over time. Thus, new therapeutic strategies need to...

Descripción completa

Detalles Bibliográficos
Autores principales: Roulin, Didier, Waselle, Laurent, Dormond-Meuwly, Anne, Dufour, Marc, Demartines, Nicolas, Dormond, Olivier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160413/
https://www.ncbi.nlm.nih.gov/pubmed/21791089
http://dx.doi.org/10.1186/1476-4598-10-90

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3160413/
https://www.ncbi.nlm.nih.gov/pubmed/21791089
http://dx.doi.org/10.1186/1476-4598-10-90

Ejemplares similares